{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:37:19Z","timestamp":1794620239265,"version":"4.9.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcyt.2026.102886","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:15:49Z","timestamp":1776075349000},"page":"102886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The future of clinical trials of mesenchymal stromal cells in acute graft-versus-host-disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-7214","authenticated-orcid":false,"given":"Areez","family":"Shafqat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-4740","authenticated-orcid":false,"given":"Abba","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102886_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J Orthop Res"},{"key":"10.1016\/j.jcyt.2026.102886_bib0002","first-page":"557","article-title":"Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use","volume":"16","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0003","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Blanc","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2026.102886_bib0004","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2026.102886_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2025.01.005","article-title":"ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells","volume":"27","author":"Blanc","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0006","doi-asserted-by":"crossref","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies","volume":"6","author":"Levy","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jcyt.2026.102886_bib0007","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2016.12.006","article-title":"Pericytes of multiple organs do not behave as mesenchymal stem cells in vivo","volume":"20","author":"Guimar\u00e3es-Camboa","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102886_bib0009","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/jcb.20886","article-title":"Mesenchymal stem cells as trophic mediators","volume":"98","author":"Caplan","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jcyt.2026.102886_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: an injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102886_bib0011","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2009.10.002","article-title":"Mechanisms involved in the therapeutic properties of mesenchymal stem cells","volume":"20","author":"Meirelles Lda","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jcyt.2026.102886_bib0012","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102886_bib0013","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcp.21200","article-title":"Adult mesenchymal stem cells for tissue engineering versus regenerative medicine","volume":"213","author":"Caplan","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0014","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: time to change the name!","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0016","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1089\/ten.tea.2010.0216","article-title":"What's in a name?","volume":"16","author":"Caplan","year":"2010","journal-title":"Tissue Eng Part A"},{"key":"10.1016\/j.jcyt.2026.102886_bib0017","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fimmu.2012.00297","article-title":"Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion","volume":"3","author":"Eggenhofer","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0019","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcyt.2025.03.137","article-title":"Mesenchymal stromal cells reprogram neutrophils to inhibit t-cell proliferation","volume":"27","author":"Tomaipitinca","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102886_bib0021","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jcyt.2024.04.014","article-title":"Mechanisms of mesencymal stromal cells phagocytosis by monocytes","volume":"26","author":"Lefsihane","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0022","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/stem.2779","article-title":"Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells","volume":"36","author":"de Witte","year":"2018","journal-title":"Stem Cells"},{"issue":"416","key":"10.1016\/j.jcyt.2026.102886_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0024","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2018.214767","article-title":"Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cell activity","volume":"104","author":"Cheung","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102886_bib0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0026","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","article-title":"Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population","volume":"16","author":"Lucchini","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0027","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12185-011-0989-2","article-title":"Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study","volume":"95","author":"Herrmann","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0028","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition","volume":"1","author":"Fisher","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcyt.2026.102886_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102886_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcyt.2026.102886_bib0031","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0032","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/stemcells.2009.121","article-title":"Stem-cell drug fails crucial trials","author":"Baker","year":"2009","journal-title":"Nat Rep Stem Cells"},{"key":"10.1016\/j.jcyt.2026.102886_bib0034","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt0712-571b","article-title":"Canada approves stem cell product","volume":"30","author":"Cyranoski","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0035","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","article-title":"Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD","volume":"16","author":"Martin","year":"2010","journal-title":"Biol Blood Marrow Transp"},{"key":"10.1016\/j.jcyt.2026.102886_bib0036","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","article-title":"A phase 3 randomized study of Remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease","volume":"26","author":"Kebriaei","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0037","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nbt1213-1061","article-title":"Mesoblast acquires Osiris' stem cell business","volume":"31","author":"Waltz","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0038","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","article-title":"Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study","volume":"103","author":"Muroi","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0039","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-013-1399-4","article-title":"Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I\/II study","volume":"98","author":"Muroi","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0040","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","article-title":"Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence","volume":"56","author":"Murata","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0041","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2020.01.026","article-title":"Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0042","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A Phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0043","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0044","unstructured":"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-prevention-or [accessed 16.11.25]."},{"key":"10.1016\/j.jcyt.2026.102886_bib0045","unstructured":"https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/ryoncil [accessed 16.11.25]."},{"key":"10.1016\/j.jcyt.2026.102886_bib0046","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3324\/haematol.2010.038356","article-title":"Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I\/II clinical trial","volume":"96","author":"P\u00e9rez-Simon","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102886_bib0047","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","article-title":"Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease","volume":"20","author":"S\u00e1nchez-Guijo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0048","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/leu.2015.89","article-title":"Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells","volume":"29","author":"Te Boome","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102886_bib0049","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41409-020-0955-9","article-title":"Early cessation of a randomised study in acute graft versus host disease: upfront mesenchymal stromal cells with corticosteroids versus corticosteroids alone","volume":"55","author":"Purtill","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","article-title":"Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0051","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12916-024-03782-5","article-title":"Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial","volume":"22","author":"Jiang","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12916-024-03275-5","article-title":"Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial","volume":"22","author":"Fu","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436653","article-title":"Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up","volume":"15","author":"Niu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0054","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13287-025-04446-8","article-title":"Salvage treatment of steroid-refractory acute GVHD with the off-the-shelf product of human umbilical cord mesenchymal stromal cells: a multicenter, open label, phase Ib\/IIa trial","volume":"16","author":"Zhao","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JBM.S546632","article-title":"Baseline CD4(+)\/CD8(+) T(EMRA) levels and early response predict survival after umbilical cord-derived mesenchymal stem cells infusion in acute GVHD patients: a randomized double-blinded placebo-controlled multicentre clinical trial","volume":"16","author":"Chin","year":"2025","journal-title":"J Blood Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0056","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","article-title":"Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation","volume":"21","author":"Zhao","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0057","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","article-title":"Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102886_bib0058","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/cells8121577","article-title":"Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation \u201cMSC-FFM\u201d-outcome report of 92 patients","volume":"8","author":"Bonig","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jcyt.2026.102886_bib0059","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey","volume":"101","author":"Ku\u00e7i","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102886_bib0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","article-title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","volume":"53","author":"Bader","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0061","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12967-023-04731-1","article-title":"Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease","volume":"21","author":"Bonig","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0062","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jcyt.2025.03.026","article-title":"Real-world outcomes of severe, heavily pre-treated aGvHD with the proprietary mesenchymal stromal cell preparation MSC-FFM","volume":"27","author":"B\u00f6nig","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0063","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.17700","article-title":"Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease \u2013 a real-world outcomes analysis","volume":"195","author":"Abedin","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101401","article-title":"Cymerus\u2122 iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease","volume":"35","author":"Ozay","year":"2019","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jcyt.2026.102886_bib0065","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","article-title":"Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study","volume":"26","author":"Bloor","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0066","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-024-02990-z","article-title":"Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0067","first-page":"1017","article-title":"Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials","volume":"91","author":"Lu","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102886_bib0068","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcyt.2024.05.007","article-title":"International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges","volume":"26","author":"Alsultan","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0069","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jcyt.2012.10.002","article-title":"The mesenchymal stromal cells dilemma\u2013does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?","volume":"15","author":"Galipeau","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0070","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jcyt.2025.03.079","article-title":"Verification of changes in cells and extracellular vesicles associated with the passage of adipose tissue-derived mesenchymal stromal cells","volume":"27","author":"Abe","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0071","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbmt.2011.07.023","article-title":"Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy","volume":"18","author":"von Bahr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1600019","article-title":"Mesenchymal stromal cells for steroid-refractory biopsy-proven grade III-IV acute graft-versus-host disease with predominant gastrointestinal involvement","volume":"16","author":"Bukauskas","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0073","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","article-title":"Current perspectives on mesenchymal stromal cell therapy for graft versus host disease","volume":"20","author":"Kadri","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0074","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13287-025-04361-y","article-title":"Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their immunomodulatory properties","volume":"16","author":"Mebarki","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62544-8","article-title":"Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs","volume":"14","author":"Kannan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102886_bib0076","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/j.bbmt.2017.12.577","article-title":"Human mesenchymal stem cells primed by interferon-\u03b3 ameliorate Gvhd in NOD\/Sicd mice through indoleamine 2,3-dioxygenase activity","volume":"24","author":"Koo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0077","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13287-020-01659-x","article-title":"GVHD-derived plasma as a priming strategy of mesenchymal stem cells","volume":"11","author":"Silva-Carvalho","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"1S Suppl 1","key":"10.1016\/j.jcyt.2026.102886_bib0090","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1097\/TA.0000000000002225","article-title":"The effects of cell type and culture condition on the procoagulant activity of human mesenchymal stromal cell-derived extracellular vesicles","volume":"87","author":"Chance","year":"2019","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcyt.2026.102886_bib0091","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1089\/scd.2015.0120","article-title":"Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua","volume":"24","author":"Moll","year":"2015","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.jcyt.2026.102886_bib0078","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcyt.2014.01.417","article-title":"Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the quantum cell expansion system","volume":"16","author":"Hanley","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0079","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13287-024-03968-x","article-title":"Induced pluripotent stem cell-derived mesenchymal stem cells: whether they can become new stars of cell therapy","volume":"15","author":"Wu","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0080","doi-asserted-by":"crossref","first-page":"111847","DOI":"10.18632\/oncotarget.22915","article-title":"CRISPR\/Cas9-mediated reversibly immortalized mouse bone marrow stromal stem cells (BMSCs) retain multipotent features of mesenchymal stem cells (MSCs)","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2026.102886_bib0081","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.stemcr.2014.05.003","article-title":"Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo","volume":"3","author":"Chinnadurai","year":"2014","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102886_bib0082","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/14653249.2011.623691","article-title":"Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-\u03b3 licensing","volume":"14","author":"Fran\u00e7ois","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0083","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0084","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0085","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.12.020","article-title":"Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease","volume":"154","author":"Pan\u00e9s","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2026.102886_bib0086","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2012.12.134","article-title":"Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism","volume":"431","author":"Tatsumi","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"1 Suppl. 1","key":"10.1016\/j.jcyt.2026.102886_bib0087","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/TA.0000000000001485","article-title":"Procoagulant activity of human mesenchymal stem cells","volume":"83","author":"Christy","year":"2017","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcyt.2026.102886_bib0088","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.transproceed.2017.03.078","article-title":"Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review","volume":"49","author":"Wu","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jcyt.2026.102886_bib0089","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0092","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0093","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/sctm.18-0015","article-title":"Clinical cellular therapeutics accelerate clot formation","volume":"7","author":"George","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0094","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13287-020-1572-7","article-title":"Infusion-related thrombogenesis by liver-derived mesenchymal stem cells controlled by anticoagulant drugs in 11 patients with liver-based metabolic disorders","volume":"11","author":"Coppin","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0095","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/jcm10132925","article-title":"Biodistribution of mesenchymal stromal cells after administration in animal models and humans: a systematic review","volume":"10","author":"Sanchez-Diaz","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcyt.2026.102886_bib0096","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jcyt.2025.04.009","article-title":"Targeted delivery of mesenchymal stromal cells (MSCs) for refractory gastrointestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT): a novel intraarterial approach","volume":"27","author":"Alexander","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1670649","article-title":"Mesenchymal stromal cell-laden hydrogels in tissue regeneration: insights from preclinical and clinical research","volume":"16","author":"Barbon","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0098","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1089\/ten.tea.2012.0665","article-title":"Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function","volume":"19","author":"Kim","year":"2013","journal-title":"Tissue Eng Part A"},{"key":"10.1016\/j.jcyt.2026.102886_bib0099","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.tibtech.2018.03.001","article-title":"Single-cell microgels: technology, challenges, and applications","volume":"36","author":"Kamperman","year":"2018","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2023.04.013","article-title":"Characterization of CRISPR\/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects","volume":"25","author":"Huang","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41551-024-01195-6","article-title":"Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression","volume":"8","author":"Sirpilla","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2026.102886_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105775","article-title":"Long-term <em>in vivo<\/em>monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging","volume":"116","author":"Shao","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jcyt.2026.102886_bib0103","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/bloodadvances.2020001711","article-title":"Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102886_bib0104","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcyt.2017.03.076","article-title":"Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy","volume":"19","author":"de Wolf","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0105","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41598-023-28478-3","article-title":"Assessment of the therapeutic role of mesenchymal stromal cells in a mouse model of graft-versus-host disease using cryo-imaging","volume":"13","author":"Wuttisarnwattana","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102886_bib0106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0107","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.celrep.2018.02.013","article-title":"Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach","volume":"22","author":"Chinnadurai","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102886_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708950","article-title":"Dichotomic potency of IFN\u03b3 licensed allogeneic mesenchymal stromal cells in animal models of acute radiation syndrome and graft versus host disease","volume":"12","author":"Chinnadurai","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102886_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06036","article-title":"A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells","volume":"7","author":"Chieregato","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.jcyt.2026.102886_bib0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2023.09.001","volume":"26","author":"Robb","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0111","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/stem.1386","article-title":"Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Jitschin","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2026.102886_bib0112","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/leu.2011.384","article-title":"Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring","volume":"26","author":"Dander","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102886_bib0113","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2018.02.001","article-title":"Immunomonitoring of MSC-treated GvHD patients reveals only moderate potential for response prediction but indicates treatment safety","volume":"9","author":"Keto","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102886_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217572","article-title":"Lymphocyte counts may predict a good response to mesenchymal stromal cells therapy in graft versus host disease patients","volume":"14","author":"Hinden","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102886_bib0115","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/sctm.20-0099","article-title":"Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study","volume":"9","author":"Boberg","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102886_bib0116","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.3390\/ijms25126731","article-title":"Repeated infusions of bone-marrow-derived mesenchymal stem cells over 8 weeks for steroid-refractory chronic graft-versus-host disease: a prospective, phase I\/II clinical study","volume":"25","author":"Kim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2026.102886_bib0117","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13287-019-1449-9","article-title":"Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease-a gut feeling","volume":"10","author":"Gavin","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102886_bib0118","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41375-018-0183-0","article-title":"A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD","volume":"32","author":"Sauer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102886_bib0119","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41409-021-01442-3","article-title":"Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers","volume":"56","author":"Kasikis","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0120","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis","volume":"3","author":"Hashmi","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102886_bib0121","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jcyt.2025.06.005","article-title":"Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases","volume":"27","author":"Davies","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102886_bib0122","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41409-024-02252-z","article-title":"Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis","volume":"59","author":"Baccelli","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0123","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbmt.2018.11.017","article-title":"Etanercept as treatment of steroid-refractory acute graft-versus-host disease in pediatric patients","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0124","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705761","article-title":"Infliximab for GVHD therapy in children","volume":"40","author":"Sleight","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0125","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.bbmt.2016.09.016","article-title":"A prospective study of alemtuzumab as a second-line agent for steroid-refractory acute graft-versus-host disease in pediatric and young adult allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0126","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbmt.2009.03.012","article-title":"Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement","volume":"15","author":"Martin","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102886_bib0127","first-page":"185","article-title":"Response-adaptive randomization in clinical trials: from myths to practical considerations","volume":"38","author":"Robertson","year":"2023","journal-title":"Stat Sci"},{"key":"10.1016\/j.jcyt.2026.102886_bib0128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/biostatistics\/kxt010","article-title":"Adaptive enrichment designs for clinical trials","volume":"14","author":"Simon","year":"2013","journal-title":"Biostatistics"},{"key":"10.1016\/j.jcyt.2026.102886_bib0129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/jnci\/djy196","article-title":"Seamless designs: current practice and considerations for early-phase drug development in oncology","volume":"111","author":"Hobbs","year":"2018","journal-title":"J Natl Cancer Instit"},{"key":"10.1016\/j.jcyt.2026.102886_bib0130","unstructured":"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry. [accessed 16.11.25]."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102886_bib131","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"New Eng J Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:25:09Z","timestamp":1788362709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":131,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1465324926008479"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102886","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of clinical trials of mesenchymal stromal cells in acute graft-versus-host-disease","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102886"}}